Mike Hooven, Founder Of AtriCure And Enable Injections, Joins Genetesis Board Of Directors

Published: Oct 11, 2017

Veteran Medical Device Entrepreneur Adds Experience, Connections to Cardiac Imaging Startup

MASON, Ohio--(BUSINESS WIRE)--Genetesis, a medical technology company that gives doctors an accurate, non-invasive tool for seeing how the heart beats, announces the addition of Mike Hooven to its Board of Directors.

Hooven is a serial medical device entrepreneur, engineer and product design expert with over 30 years of experience founding transformative companies including AtriCure (NASDAQ:ATRC) and Enable Injections. He holds more than 100 issued and pending US patents.

“I am delighted to be joining the Genetesis team. They are creating a completely new way to see and diagnose what is going on inside the human body,” said Hooven. “I am looking forward to providing whatever insight and experience I can to guide them on this very exciting journey.”

Genetesis is developing CardioFlux™, a biomagnetic imaging device, to revolutionize chest pain triage in hospital emergency departments. Currently, the widely used electrocardiogram (ECG or EKG) provides a snapshot of heart rate and rhythm during the test, but does not reflect many underlying problems that may exist when a patient is not experiencing symptoms. CardioFlux™ gives physicians 3D mapping tools, to understand each patient’s underlying electrical activity, which can potentially be used to diagnose, characterize, and guide treatment for a variety of cardiac disorders.

Since closing a seed financing from investors including Mark Cuban and CincyTech, Genetesis has presented findings from a collaboration with the Mayo Clinic, and started a clinical study at St. John Hospital and Medical Center in Detroit. Genetesis won the Nvidia Inception Award for “Best AI Social Impact Startup,” and was named VentureOhio’s Seed Stage Company of the Year.

“Mike Hooven is one of the foremost medical device innovators in the Midwest. His track record of building companies like AtriCure and Enable Injections speaks for itself,” said Genetesis CEO Peeyush Shrivastava. “He brings decades of successful medical device operating experience and tremendous value to our Board.”

ABOUT GENETESIS

Genetesis is a medical technology company developing CardioFlux™, a non-invasive platform using magnetic measurements to map the heart’s electrical currents for detection and treatment of cardiovascular disease.

Genetesis
Peeyush Shrivastava
peeyush@genetesis.com

Back to news